“Triple-negative” refers to a heterogenous and highly aggressive group of breast cancers (BC) that are immunohistochemically characterized by both the lack of estrogen (ER) and progesterone (PR) receptors and the absence of human epidermal growth factor receptor 2 gene (HER2) amplification. The gene discussed is ERBB2; the disease is breast carcinoma.